Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients

ClinicalTrials.gov ID: NCT01599754

Public ClinicalTrials.gov record NCT01599754. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.

Study identification

NCT ID: NCT01599754
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: SFJ Pharma Ltd. II; Industry
Enrollment: 724 participants

Conditions and interventions

Conditions

Clear Cell Renal Carcinoma

Interventions

Axitinib Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2012
Primary completion: Oct 9, 2017
Completion: Apr 30, 2018
Last update posted: Sep 19, 2019

2012 – 2018

United States locations

U.S. sites: 26
U.S. states: 16
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	La Jolla	California	92093	—
Not listed	Los Angeles	California	90033	—
Not listed	Palo Alto	California	94304	—
Not listed	Pleasant Hill	California	94523	—
Not listed	Denver	Colorado	80218	—
Not listed	Washington D.C.	District of Columbia	20007	—
Not listed	Ocala	Florida	34471	—
Not listed	Atlanta	Georgia	30322	—
Not listed	Annapolis	Maryland	21403	—
Not listed	Baltimore	Maryland	21231-1000	—
Not listed	Saint Paul	Minnesota	55118	—
Not listed	Omaha	Nebraska	68198	—
Not listed	Hackensack	New Jersey	07601	—
Not listed	Albany	New York	12208	—
Not listed	New York	New York	10467	—
Not listed	Portland	Oregon	97227	—
Not listed	Charleston	South Carolina	29412	—
Not listed	Chattanooga	Tennessee	37421	—
Not listed	Austin	Texas	78731	—
Not listed	Bedford	Texas	76022	—
Not listed	Dallas	Texas	75203	—
Not listed	Houston	Texas	77024	—
Not listed	San Antonio	Texas	78217	—
Not listed	San Antonio	Texas	78234	—
Not listed	Norfolk	Virginia	23502	—
Not listed	Seattle	Washington	95109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01599754, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 19, 2019 · Synced Sep 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01599754 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →